mRNA-transfected autologous dendritic cells

A personalized immunotherapy approach where dendritic cells are collected from a patient, transfected with messenger RNA (mRNA) encoding specific antigens (such as tumor-associated antigens), and then reinfused into the patient to stimulate an immune response against targeted diseases, particularly cancer. This approach represents a personalized immunotherapy strategy that leverages the natural role of dendritic cells as powerful antigen-presenting cells. By transfecting these cells with mRNA encoding tumor-associated antigens, the therapy aims to induce potent T cell-mediated immune responses against cancer cells. ## Mechanism and Advantages The process involves isolating dendritic cells from the patient, transfecting them with mRNA encoding specific antigens (such as prostate-specific antigen in prostate cancer or tumor-associated antigens in melanoma), and then administering the modified cells back to the patient. This approach offers several advantages: 1. The transfection process is simple and effective, with high transfection efficacy and viability. 2. Unlike peptide-based approaches, mRNA transfection is not limited by HLA restrictions, eliminating the need for patient selection based on HLA expression. 3. mRNA can be generated and characterized more easily than protein for clinical use. 4. The approach has demonstrated the ability to induce antigen-specific T cell responses in both preclinical models and clinical trials.